A Phase 1 interventional study of KRG hard capsule and Placebo hard capsule in Healthy, sponsored by Centre of Clinical Pharmacology, Hanoi Medical University. Completed at 1 site in Vietnam. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-31.
Sponsored by Centre of Clinical Pharmacology, Hanoi Medical University · Phase 1, Interventional, and Supportive care
This is a placebo-controlled, randomized, double-blind, multiple dose study that evaluated the safety, tolerability, and changes in indicators of immune function of Korean Red Ginseng Extract in Vietnamese healthy subjects following oral administration of multiple dose of Korean Red Ginseng Extract as hard capsules or placebo to healthy adult men.
Centre of Clinical Pharmacology, Hanoi Medical University is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Each KRG hard capsule contains 500 mg of red ginseng extract. Dosage of KRG hard capsule: oral administration of 1 capsule twice daily for 12 weeks.
Drug: KRG hard capsule
The composition of the Placebo hard capsule contains red ginseng flavor. Dosage of Placebo hard capsule: oral administration of 1 capsule twice daily for 12 weeks.
Drug: Placebo hard capsule
Each subject was given orally 2 KRG hard capsules/day for 12 weeks
Each subject was given orally 2 placebo hard capsules/day for 12 weeks
Adverse events associated with the administration of KRG
Frequency and characteristics of adverse events associated with the administration of KRG
Time frame: 12 weeks
Natural killer (NK) cell count
Change in NK cell count after 12 weeks compared to baseline
Time frame: 12 weeks
White blood cell count
Change in white blood cell count after 12 weeks compared to baseline
Time frame: 12 weeks
Interferon (IFN)-α, β, γ levels
Changes in IFN-α, β, γ levels after 12 weeks compared to baseline
Time frame: 12 weeks
Tumor necrosis factor (TNF)-α, β, γ levels
Changes in TNF-α, β, γ levels after 12 weeks compared to baseline
Time frame: 12 weeks
Interleukin (IL)-1, 4, 6 levels
Changes in IL-1, 4, 6 levels after 12 weeks compared to baseline
Time frame: 12 weeks
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre of Clinical Pharmacology, Hanoi Medical University